Skip to main content

Table 1

From: Featuring the phenotype of the FMF prototype

Parameter 694 Homozygous (N=57) Other mutations (N=56) P
Average length of attack (days) 2.66±1.5 3.03±1.2 0.073
Abdominal attacks 50 (87.7%) 48 (85.7%) 0.788
Arthritis attacks 52 (91.3%) 28 (50%) <0.0001
Pleuritis attacks 36 (46.2%) 18 (38.2%) 0.0013
Exertional leg-pain 47 (82.5%) 36 (64.3%) 0.034
ELE attacks 10 (17.5%) 3 (5.4%) 0.073
Attacks of fever alone 20 (35.1%) 12 (21.4%) 0.143
Average colchicine dose (mg/day) 1.9±0.48 1.48±0.54 0.0001
IV colchicine treatment 5 (8.8%) 0 (0%) 0.057
Proteinuria or amyloidosis 6 (10.5%) 1 (1.8%) 0.113
Anemia of chronic disease 14/53 (26.4%) 7/52 (13.5%) 0.142
Elevated acute phase reactants 10/18 (55.6%) 4/16 (25%) 0.092
Chronic renal failure 6 (10.5%) 0 (0%) 0.027
Chronic arthritis 11 (19.3%) 2 (3.6%) 0.015
Work days lost each month 4.4±7.2 2.6±4.6 0.718
Harm to quality of life (1-10) 5.6±3.3 4.1±3 0.013
Number of attacks per year w colchicine 7.2±7.8 3.5±5.5 0.0007
Number of attacks per year w/o colchicine 23.6±9.3 15.6±11.7 0.0001
Crohn's disease 4 (7%) 2 (3.6%) 0.679
Ankylosing Spondylitis 3 (5.3%) 1 (1.8%) 0.619
Behcet's Disease 7 (12.3%) 1 (1.8%) 0.061
Henoch Schonlein Purpura 1 (1.8%) 0 1
All FMF associated diseases 17 (29.8%) 7 (12.5%) 0.0373